The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
The majority of patients with non–small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third‐generation, mutation‐selective EGFR inhibitor. The current study focuses on determining whether targeting MEK/ERK signaling prevents or delays the development of acquired resistance to osimertinib.
Methods...
Background
The major clinical obstacle that limits the long‐term benefits of treatment with osimertinib (AZD9291) in patients with epidermal growth factor receptor‐mutant non–small cell lung cancer is the development of acquired resistance. Therefore, effective strategies that can overcome acquired resistance to osimertinib are urgently needed. The authors' current efforts in this direction have...
Background
Osimertinib (AZD9291), a third‐generation, mutation‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR‐TKI), is an approved drug for patients who have non–small cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. Unfortunately, all patients eventually relapse and develop resistance to osimertinib. The current...
Background
The thoracic radiotherapy (TRT) target volume for limited‐stage small‐cell lung cancer (SCLC) has been controversial for decades. In this report, the final results of a prospective randomized trial on the TRT target volume before and after induction chemotherapy are presented.
Methods
After 2 cycles of etoposide and cisplatin, patients arm were randomized to receive TRT to the postchemotherapy...
BACKGROUND:Reliable predictive biomarkers are required to address the challenge of disease recurrence after thyroid cancer surgery. For this study, the authors assessed the association of cellular‐based and serum‐based immunologic mediators with thyroid cancer recurrence.
METHODS:Leukocyte subset counts and immune regulatory cytokine levels were determined in peripheral blood samples using multiparameter...
BACKGROUND:Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in nonsmall cell lung cancer (NSCLC). The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC.
METHODS:Patients with advanced stage NSCLC and progression after prior platinum‐based chemotherapy were eligible. Sequential cohorts were...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.